Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/12/2024
• Auteurs : Yoann GaboreauPaul FrappéCeline VermorelAlison FooteJean-Luc BossonGilles PernodNathan AbenhaïmSophie AckermannMaryse Adam BlanpainXavier AndreuCéline ArnouldAudrey Atlan-CottinJean-Pierre AubertIsabelle Aubin-AugerJacques AubryJulien AugueuxVeena AugustinAnnick BakryMarine BaldesiEric BanounEric BarberetRémi BardetFlorence BarriereDan BaruchNicolas BaudeMarc BayenSabine BayenFrançois BayleYannick BeaufilsAlain BeaupinJulie Bedel-ChauvaudRaphaël BelMartine BellierFarouk BendamenePhilippe BerardCédric BerbéChristophe BerkhoutJacques BerlandCharles-Edouard BéthembosPierre-Yves BilliardOlivier BischAurélie BizeauPaul BlanchardGuy BlanquartAurélie BochIsabelle BodeinEmmanuel BoigeClaude BoninAnne-Laure BonisMarie-Pierre BonnardPascal BonnetPierre-André BonnetGérard BosselutAnne BottetPhilippe BoucheBérengère BoucherleAudrey BougeardSerge BouhanaMourad BoukeloulJean Boulet-GercourtJean-Marie BoulongneLionel BouniolJean-Jacques BourcartMichel BourgoinVéronique Bourguignon-VartanianClaire BoutevillePhilippe BoutinAnnelore BoutmyEvelyne Brenner-GiraultNicolas BretonMuriel Briane-FraysseMarina BrodbeckOlivier BrunetAriel BuchingerAnne Buffaz-SutraMarc BurPhilippe CabourdinPhilippe CacheraEric CailliezMatthieu CalafioreDenis CalvetPierre CamedescasseHervé CanartMichel CancadeChristophe CandelierChristian CapiodThierry CarinOlivier CaronElisa CarréYannick CarrilloNathalie CasagrandePierre CausseGaëlle ChabertFrédérick ChabordJuliette ChambeGuillaume ChambonRichard ChampeauxLaurent CharbonnelRodolphe CharlesClément CharraSamuel ChartierJulie ChastangSophia ChatelardEric ChatillonLaurent ChauvotHervé ChelleStéphane ChenuetNicolas ChevalierDavid ChevillotJean-Pierre CibeerJacques CittéeJean-François ClaudelYvonnick ClemenceJean-Paul ClergetIsabelle Clusier-JeudyMarie-Pierre CoispeauArnaud ColinHervé Collart-DutilleulLaurence CompagnonMarine Compan MaletLaurent ConnanHubert ConradBruno CoquillaudJean-Luc CormierJean-Charles CouetteYves CournoyerChristian CousinStephen CretonJean-Jacques CrignonAndré CrosMichel CuninEmmanuel CussacJean-Maurice DaillyDidier DanvinPierre-Marie DarnautBruno DaubinThomas de L’hamaideYves de Saint MeleucSabine de TaddeoJean-Luc DeckerAnne DecobertYannick DelattreChristine DelavenneLoïc DelavenneBénédicte DelbruDenis DeleplanqueNicole DeleriveLaurent DelesalleFrançois DelforgeJean-Paul DelgrangeJean-Pierre DelpierreEric DemeulemeesterNicolas DerainFabrice DescombeThierry DesmoulinsMarie-Claire Deville-CarolloJean-Michel DherbecourtMichael DidierjeanSalima DomraneBrigitte DouzouSabine DruartXavier DubeauArnaud DubedatRésika DudragneChristian DuezLucien DufourSylvie DuhamelLionel DuisitNathalie DumoitierHervé DumondJulien DumortierEmilie DuquesneDavid DurandWilliam DurieuxPhilippe DurotTaous DussBénédicte EschalierEric EspiardPierre EtersteinJoël EtienneyXavier FaidixPatrice FameryDavid FariaRenaud FaureAndré FerrerJean-Marie FerrerJean FeuilletChristian FivelChristian FlaissierJulien FortanéJenny FortéClaude FosséJoël FoucatChristophe FouillardVianney FournierVirginie FournierDéborah FraizyPaul FrappéIsabelle Frenoy-SansarricqBernard GabbaiYoann GaboreauFabien GaillardIsabelle GarnierJean-Michel GarnierJean-Claude GascoinYves GaultMartine GaultierBruno GayBenoît GédonChristophe GeniesJean-Marc GénioleJean-Luc GentnerJean-Louis GhezCharles GiraldiChristian GirardPhilippe GiraudSylvain GodartPierre GoidinAline GomezCéline GoncalvesArnaud GougetMarie-Laure GougetSylvain GournayFlorence GrandJean-Claude GranierRoland GreffeSabine GrutterCatherine GrybFrançois-Xavier GuedelMathieu GuérinJulien GuiberteauJean-François GuilleJean-Pierre GuillotPhilippe GuillouGilles GustinAnne GuyotJean-Marie GuyotChristophe HardyDavid HassidLatifa HayaniAnne HellerFrédéric HenriotThierry HermouetBénédicte Hoenner HechtFerreol Honvoh SenadjroGaëtan HoudardIsabelle Huas-SuarezCorinne HuberPatrick ImbertPascal JacquesCécile JacquetJean-Pierre JacquetDenis JacquiotPhilippe JacquotSamy JaffreClémence JeanPauline JeanmouginIsabelle JeudyJean-Philippe JosephPierre JouannicStéphanie JoussonAndré KastelikGérard KlifaFrançois-René KnockaertJean-Philippe KochJulia KrotoffCharlotte LabruneVéronique Lacaille-SmerilliFrançois LacoinXavier LainéPhilippe LambertAudrey LambourgDominique LamyMyriam Lapenne-CreusotJean-Dominique LaporteLucie LartaudNadège LauchetDorothée LavielleJulien Le BretonRaphaël Le DiagonMarie Le DuDelphine Le GoffClaire Le LannStéphane Le MouëlCarole Leblan-DepelsenaireFrédéric LeclercqRudolphe LécutierJean-Nicolas LedouxJean-Marc LefebvrePascal LégerRobert LendaisEric LengagneCatherine Sosiewicz-LengsavathSylvie LenoirPatrick LerougeBenoît LeroyIda Leung-Y-TaiPascal LigierCharlotte LobelFrançois LoezBéatrice LognosBaptiste LuacesLaurence Lucas-CouturierAnne LunvenSigolène MachraouiAndré MaciejewskiLoïc MagnenGeorgios MakridisJean-Luc MalbrunotJean-Marc ManciniHervé ManginJean-Marc ManiglierPhilippe MarchantJulie MarcusGuillaume MarienAnne-Laure Martin-EtzolChristian MasYannick MassetPierre MassinBruno MassonAgnès MatteraCharlotte MatzFrançois MaufoyCollette MauryLaure-Emmanuelle MavraganisOlivier MazinLison MazuéJean-Philippe MelizanDominique MenardAlain MercierPatricia MercierPatric-Alain MeyerPhilippe MichellierCorinne MilleretYannick MillotFrançoise MinardMarie-Léa MiqueuDany MismacqueCatherine MitifiotJean-Louis MoebsJean-Michel MonnierYves MontariolJérémie MontauzeAlain MorandGilles MorelFrançois MorlonDelphine MortasBaptiste MotteStéphane MougetLuc MunroMartin NaessensBounthanousone NammathaoDominique NegreCharlie NogrelLucile NouvelletIsmaël Nureni BanafunziThierry OgerJean-François OrtholanDominique OstyAgnès Oude EngberinkGuy-Marc PaillardLaurent PaillardMarie-Paule Pautout-GuillaumeLaurent Pech-GourgCorinne PerdrixVéronique PerezSégolène Perrillat-AmédéChristophe PeyrouBruno PichatChristophe PigacheAlexis PinotDominique PiquardThierry PiquetMichel PlacetMichel PlauchierCaroline PluskotaMaurice PonchantChantal PratMartine PrevostJean-Pierre PrigentThibaut PyChristian RafinJacques RambaudJean-Paul RapoudAnne-Marie RegnierSylvain RenaudinJean-Michel RétauxAmélie RichardPhilippe RichettaJean-Michel RigaultReinold RigoliAnne Ritter-MeinickeSarah RobertStéphanie RollinDidier RondepierreSophie RosenbergMélanie RothFabien RougerieGuillaume Royer de VericourtKaren RudellePhilippe RuelleMarcel RuetschDominique SaillardPénélope Saint-DenisPietro SannelliPhilippe SaraidarianJean-Pascal SastournéLaurent SauvageChristian ScellierChristian SchaalFrançois-Xavier SchelcherDaniel SchirlinAnne SchirrerClaude SchliengerJoëlle SchliengerPhilippe SerayetDenis SerramouneMarlène SieblerJean-Paul SimonAndré SoaresCarine Soussotte-DucassePhilippe StefanutoMarc SteinbergerMarianne SzapiroAnas TahaErol TaluyGilles TanguyDominique TardieuxMichel TardyBenoît TavernierJean-Luc TénédosLorène Thelot-BachRémy TisserandAudrey TordoirFrançois TrillotPascal TriouleyreDavid TruongLaurent TuriFrédéric VaillantHélène Vaillant-RousselPierre VaillerJosette ValleeMuriel VampouilleJean-Louis VangiFabien VannierSimon VarinFlorence VaugeoisJean‐charles VauthierVirginie VauthierDelphine VeillardAnne-Laure VerjusPaul-Bernard VerjusGilles VerneyEloïse VialtelFernand VierlingGraziella Virgone-RebaudMarc Vital-DurandEric VittoriNadège VolclerPhilippe VorilhonPierre WatteauChristine WeisbeckerNathalie WeyFrançoise Wilhelm-NenotJean-Louis WurtzPatricia YvonClaire ZabawaJean-Marc ZamboniAnne-Claire Zipper
• Organismes : Modélisation et Évaluation des données complexes en Santé Publique U 1059 – SAINBIOSE Bio-ingénierie Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] Modélisation et Évaluation des données complexes en Santé Publique CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Université Grenoble Alpes F-Crin INvestigation Network On Venous Thrombo-Embolism [CHU Saint-Etienne] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Université Grenoble Alpes Procédés Alimentaires et Microbiologiques [Dijon] Aliment, Fermentation, Interaction, Microbiote Antibioclic [Paris, France] Université Paris Cité Université de Nantes Direction de la Recherche Clinique et de l’Innovation [CHU Clermont-Ferrand] Département de Médecine Générale [Clermont-Ferrand] AutomédiCation aCcompagnement Pluriprofessionnel PatienT
• Publié dans Family Practice le 23/10/2020

---

Résumé : Abstract Background The ability of bleeding risk scores to predict major bleeding (MB) or clinically relevant nonmajor bleeding (CRNMB) remains a topic of contention, particularly in nonselected patients in family practice. In addition, the capacity to predict bleeding risk using simple variables has yet to be established. Objectives The main objective was to confirm that severe anemia was the most predictive factor for the estimation of bleeding risk in patients treated with vitamin K antagonists (VKAs). Secondary objectives were to test the capacity of different bleeding scores to detect high-risk patients. Subsequently, the impact of functional decline on bleeding incidence was explored. Methods The CACAO study was a multicenter prospective cohort study of patients who, due to nonvalvular atrial fibrillation (NVAF) and/or venous thromboembolism (VTE), had been prescribed an oral anticoagulant by their general practitioner (GP) as a prophylactic measure. Patient characteristics were collected at the time of inclusion by GPs, who then monitored them in accordance with standard practice for one year. MB and CRNMB were the main outcomes for one year. By applying this approach, a total of 13 scores were analyzed. Results Aaemia was found to be strongly associated with MB (HR: 2.77, 95% CI: 1.2–6.36), with a particularly pronounced association observed in cases of severe anemia (HR: 12.9, 95% CI: 2.76–60.35). Twelve out of 27 MB cases were not identified by at least half of the scores. By contrast, functional decline was identified as a novel factor associated with MB (HR: 2.45, 95% CI: 1.13–5.31). Conclusions Preexisting anemia is a major prognostic factor associated with the occurrence of bleeding. It seems relevant to suggest that functional decline should be considered by GPs when assessing bleeding risk.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 02/12/2024
• Auteurs : Anaïs MennecierBeauty MatokaMaria Melany Wilfred-TongaCatherine Chunda-LiyokaMwiya MwiyaNicolas NagotJean-Pierre MolesPhilippe Van de PerreChipepo KankasaRachel KingMorgana D’ottaviDavid RutagweraSylvester BandaFaith SitaliChayson MaundaMwape Kelvin ChisalaRichard KandelaKennedy Changwa SikambaleMwape ChibaleSara PhiriGertrude MunanjalaaVera Ndulumina KawangaEric Maseko PhiriShanzi MulengaJenala Nyirenda HapengaKapambwe Mulenga
• Organismes : Pathogenesis and Control of Chronic and Emerging Infections University Teaching Hospital [Lusaka] University Teaching Hospital [Lusaka] University Teaching Hospital [Lusaka] University Teaching Hospital [Lusaka] Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections University Teaching Hospital [Lusaka] Pathogenesis and Control of Chronic and Emerging Infections Pathogenesis and Control of Chronic and Emerging Infections
• Publié dans BMC Public Health le 22/10/2020

---

Résumé : Background: PROMISE-EPI trial evaluated a combination of interventions to prevent HIV transmission during breastfeeding. It showed a reduced postnatal transmission compared to the standard of care. The intervention combined identification of infants at high risk of infection using a point of care assay (POC) for early infant diagnosis and monitoring maternal viral load (VL) at 6 weeks and 6 months. A single-drug post-natal prophylaxis (PNP) was immediately initiated for high risk infants (maternal VL ≥ 1000 cp/mL). In Zambia, the national guidelines standard of care differs by 1) using three-drug PNP; 2) quarterly monitoring of maternal VL; 3) maternal VL testing in central labs. We explored the facilitators and barriers of this innovative prevention package to guide future scale-up. Methods: Qualitative methods were used to gather information on PROMISE-EPI trial delivery, context, and behaviors. PROMISE-EPI intervention and control participants, staff members and health care professionals were interviewed. Verbatim transcripts were coded using a priori and emerging codes. Analysis was conducted using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework. The determinants were categorized into the 5 domains of the Consolidated Framework for Implementation Research (CFIR) to better identify the causes of intervention success or failure among the 5 RE-AIM components. Results: A total of 37 individual interviews and 15 focus group discussions were conducted. Facilitators included the importance of the connection between the key elements of the intervention (POC and PNP) for immediate clinical action. Rapid maternal VL results induce several positive downstream behaviors in mothers and healthcare professionals, including increased trust in health care system. These can be quickly reversed when point of care testing is sub-optimal, as during the COVID-19 pandemic. Furthermore, the secondary elements of the intervention beyond POC and PNP; namely a warm welcome, a dedicated space, detailed and dedicated counselling, reimbursement for transport, solar panels and batteries, reminders and additional staff; were identified as facilitating its acceptability and fidelity. Conclusion: This study provides new elements to better understand the reduced HIV transmission with the PROMISE-EPI intervention. It also highlights potential gaps between the package proposed in the trial and what can be applied in less controlled, ‘real life’ settings.

---

Fichiers liés : s12889-024-20855-5.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2024
• Auteurs : Hélios BertinJean-Philippe PerrinPierre Corre
• Organismes : Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers Service de Chirurgie maxillo-faciale et stomatologie Service de Chirurgie maxillo-faciale et stomatologie Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Regenerative Medicine and Skeleton
• Publié dans Orthodontie Française le 02/11/2020

---

Résumé : Introduction L’objectif de cet article est de présenter l’approche diagnostique et thérapeutique des insuffisances verticales postérieures unilatérales. Matériel et méthodes Les auteurs exposent le protocole de prise en charge. Résultats L’insuffisance verticale postérieure (IVP) unilatérale se manifeste cliniquement par une obliquité du plan d’occlusion maxillo-mandibulaire et de la ligne bicommissurale, et par une déviation du menton. Radiographiquement, l’IVP se manifeste par une élévation de l’angle mandibulaire par rapport à la base de l’odontoïde. Parmi les étiologies, les atteintes congénitales sont les plus fréquentes et sont dominées par les hypocondylies. Les atteintes des premier et deuxième arcs branchiaux s’accompagnent, le plus souvent, de malformations associées des tissus mous, tandis que les atteintes acquises (post-traumatiques, ankyloses et atteintes rhumatismales) sont plus rares. La prise en charge nécessite une étroite collaboration orthodontico-chirurgicale et fait appel à des procédures non conventionnelles de chirurgie orthognathique. Trois techniques sont détaillées ainsi que leurs résultats attendus : la greffe chondro-costale, l’allongement vertical rétro-spigien selon la technique de Caldwell-Letterman et l’ostéotomie supra-basilaire intra-orale. Discussion Si la présentation clinique peut être fruste chez l’enfant, l’asymétrie faciale se majore le plus souvent au cours de la croissance pubertaire. Une prise en charge précoce en orthopédie dento-faciale peut parfois permettre de restaurer la croissance. Dans les autres cas, la collaboration entre l’orthodontiste et le chirurgien est plus que jamais nécessaire pour corriger l’asymétrie, parfois à l’aide de techniques chirurgicales non conventionnelles.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2024
• Auteurs : Sean L ZhengAlbert HenryDouglas CannieMichael LeeDavid MillerKathryn A McgurkIsabelle BondXiao XuHanane IssaCatherine FrancisAntonio de MarvaoPantazis I TheotokisRachel J BuchanDoug SpeedErik AbnerLance AdamsKrishna G AragamJohan ArnlovAnna Axelsson RajaJoshua D BackmanJohn BaksiPaul J R BartonKiran J BiddingerEric BoersmaJeffrey BrandimartoSoren BrunakHenning BundgaardDavid J CareyPhilippe CharronJames P CookStuart A CookSpiros DenaxasJean-Francois DeleuzeAlexander S DoneyPerry ElliottChristian ErikstrupTonu EskoEric H Farber-EgerChris FinanSophie GarnierJonas GhouseVilmantas GiedraitisDaniel F GuethbjartssonChristopher M HaggertyBrian P HallidayAnna HelgadottirHarry HemingwayHans L HillegeIsabella KardysLars LindCecilia M LindgrenBrandon D LoweryCharlotte ManistyKenneth B MarguliesJames C MoonIfy R MordiMichael P MorleyAndrew D MorrisAndrew P MorrisLori MortonMahdad NoursadeghiSisse R OstrowskiAnjali T OwensColin N A PalmerAntonis PantazisOle B V PedersenSanjay K PrasadAkshay ShekharDiane T SmelserSundararajan SrinivasanKari StefanssonGarethar SveinbjornssonPetros SyrrisMari-Liis TammesooUpasana TayalMaris Teder-LavingGuethmundur ThorgeirssonUnnur ThorsteinsdottirVinicius TraganteDavid-Alexandre TrégouëtThomas A TreibelHenrik UllumAna M ValdesJessica van SettenMarion van VugtAbirami VeluchamyW M Monique VerschurenEric VillardYifan YangFolkert W AsselbergsThomas P CappolaMarie-Pierre DubeMichael E DunnPatrick T EllinorAroon D HingoraniChim C LangNilesh J SamaniSvati H ShahJ Gustav SmithRamachandran S VasanDeclan P O'ReganHilma HolmMichela NosedaQuinn WellsJames S WareR Thomas Lumbers
• Organismes : Bordeaux population health
• Publié dans Nature Genetics le 29/10/2020

---

Résumé : Dilated cardiomyopathy (DCM) is a leading cause of heart failure and cardiac transplantation. We report a genome-wide association study and multi-trait analysis of DCM (14,256 cases) and three left ventricular traits (36,203 UK Biobank participants). We identified 80 genomic risk loci and prioritized 62 putative effector genes, including several with rare variant DCM associations (MAP3K7, NEDD4L and SSPN). Using single-nucleus transcriptomics, we identify cellular states, biological pathways, and intracellular communications that drive pathogenesis. We demonstrate that polygenic scores predict DCM in the general population and modify penetrance in carriers of rare DCM variants. Our findings may inform the design of genetic testing strategies that incorporate polygenic background. They also provide insights into the molecular etiology of DCM that may facilitate the development of targeted therapeutics.

---

Fichiers liés : BPH_NatureGen_2024_Zheng.pdf

---

Source

---

• Type de publi. :
• Date de publi. : 01/12/2024
• Auteurs : Sabrina BaakliniAlexandre SarrabayAdrien MazuelBertrand EscaliereChuang DongCamille BarthelemyLaurine GilLaila DahbiNoushin Mossadegh-KellerNathalie van AckerPauline GravelleJean-Marc NavarroCaroline HuberRomain FenouilRomane TrombettaMarine PujolPhilippe GaulardBenjamin RivierePeggy DartiguesFrancesco Llamas GutierrezCeline PangaultFabrice JardinFrançois LemonnierGilles SallesCorinne HaiounGabriel BrisouMatthew StokesSahil SethMaria Ortiz EstevezCamille LaurentLionel SpinelliMark KaplanC. Chris HuangAnita GandhiBertrand NadelSandrine RoullandPierre Milpied
• Organismes : Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre de Recherches en Cancérologie de Toulouse Institut Universitaire du Cancer de Toulouse - Oncopole Centre de Recherches en Cancérologie de Toulouse Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Hôpital Henri Mondor Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier GHU AP-HP. Université Paris Saclay Département de biologie et pathologie médicales [Gustave Roussy] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Universitaire [Rennes] = Rennes University Hospital [Pontchaillou] Microenvironment and B-cells: Immunopathology, Cell Differentiation, and Cancer Établissement Français du Sang Bretagne [Rennes] Service Anatomie et cytologie pathologiques [CHU Toulouse] Institut Universitaire du Cancer de Toulouse - Oncopole Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy Centre d'Immunologie de Marseille - Luminy

---

Résumé : Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive B-cell lymphoma with high clinical and biological heterogeneity. Despite current effective immunochemotherapy, up to 40% of patients do not respond or develop refractory disease. DLBCL is characterized by two major cell-of-origin (COO) subtypes, germinal center B cell-like (GCB) and activated B cell-like (ABC), with recent research uncovering additional molecular subgroups based on genomic alterations or tumor microenvironment (TME) features. We recently reported (Baaklini et al. ASH 2023) a multimodal single-cell atlas of 62 DLBCL cases, integrating single-cell transcriptomes, immune repertoire and genetic features, that we have leveraged to decrypt recurrent B cell states and TME ecosystems while identifying clinically relevant prognostic biomarkers. Here we report further analyses of the single-cell atlas dataset focused on TME composition and differentiation trajectories, and the validation of our main findings through cell-state deconvolution of bulk RNA-seq datasets and single-cell spatial transcriptomics analyses. Methods: The DLBCL single-cell atlas was generated with 5'-end single-cell RNA, B-cell receptor (BCR) and T-cell receptor sequencing on 63 DLBCL lymph node biopsies obtained from the real-world, clinically-annotated, multicentric CeVi collection and included 43 patient samples at diagnosis (ABC = 17, GCB = 11, Unclassified = 6, Not Evaluated = 9; 21 of which did not achieve event-free survival at 24 months (EFS24) after R-chemotherapy regimens), 11 relapsed/refractory DLBCL and 8 DLBCL transformed from indolent lymphoma. Methods for overall cell annotation and malignant B cell states identification were reported previously (Baaklini et al. ASH 2023). For the analysis of the TME and the focus on T cells, we identified clonally expanded T-cell subsets based on their TCR sequences, and used trajectory inference algorithms to track CD8 T cell branched differentiation. Validation on public, clinically annotated data (Schmitz et al. NEJM 2018) was performed by gene signature scoring and reference-based deconvolution. Single-cell spatial transcriptomics was performed on a subseries of 20 DLBCL cases laid out as tissue microarrays, using two distinct technologies with off-the-shelf 1000-plex and 377-plex panels. Results: We previously reported the identification of 5 conserved malignant B cell transcriptional archetypes (Arch.1-5) that co-exist in DLBCL samples: Arch.1 characterized by plasma cell identity, Arch.2 by MYC and NFKB pathways, Arch.3 by MYC pathway only, Arch.4 by quiescence markers, and Arch.5 by GC markers. Integrated analysis of the TME revealed three major ecosystems based on the relative proportions of non-malignant T, NK and myeloid cell subsets, including one enriched for effector and cytotoxic T cells. TCR clonal analysis revealed that the largest clonotypes were enriched in a subset of terminally differentiated hyperactivated CD8 effector T cells. Differentiation trajectory analysis of CD8 T cells revealed that patients achieving event-free survival at 24 months (EFS24) accumulated terminally differentiated hyperactivated CD8 effector T cells, while CD8 T cell differentiation was blocked at an intermediate effector stage in patients not achieving EFS24. We validated those findings by cell-type specific gene signature scoring and reference-based deconvolution of a public bulk RNA-seq dataset. Integrating proportions of malignant B cell archetypes and TME subsets, we defined 4 groups of samples with distinct event-free survival differing notably in their proportions of Arch.4 cells and terminally differentiated hyperactivated CD8 effector T cells, which we also validated by reference-based deconvolution of public bulk RNA-seq. Finally, single-cell spatial transcriptomics mapped distinct cellular neighborhoods of malignant B cells, non-malignant immune cells, and stromal cells. Conclusion: In conclusion, fine analysis of our comprehensive single-cell atlas of DLBCL revealed integrated malignant and TME characteristics associated with clinical response, that were also validated on other datasets and technologies. Those findings bring novel biomarkers for stratifying non-responsive DLBCL patients and guiding treatment decisions, as well as for designing novel therapies targeting the malignant B cell - TME crosstalk.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2024
• Auteurs : Romain BoulestreauAurélien LorthioirHervé DreauAlexandre PersuAntoine CrémerPierre-Louis TharauxSébastien RubinBenjamin MaierMikael MazighiAlice SerisMichel PaquesSophie BonninJean Michel HalimiStéphane DebeugnyPhilippe Gosse
• Organismes : Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
• Publié dans Journal of Hypertension le 23/10/2020

---

Résumé : Malignant hypertension has not disappeared and remains the most severe form of hypertension. More than 100 years after its description, many points remain unanswered. Mechanisms, definitions, and optimal treatment are still controversial. In 2019, we decided to launch a prospective multicentre multidisciplinary cohort in France to try to fill these gaps. This study aimed to describe the baseline characteristics of the first 302 included patients and compared these data to already published cohorts. We included patients with severe hypertension associated with severe hypertensive retinopathy and patients filling the HYP MOD (HYPertension MultiOrgan Damage) definition from a broad range of departments (cardiology, nephrology, neurology intensive care unit, emergency department, internal medicine). We collected clinical, biological, imaging, and target organ damage data at admission, along with social and demographic data. We also recorded diagnostic and therapeutic management, adverse events during hospitalization, and characteristics at discharge. We enrolled 302 patients in 32 months (105/year) among 40 centres and different specialties. They mainly included young men (68%, mean age 48.7 ± 14.5 years). Target organ damage involved the eye in 86.7% of patients, kidney in 58.6%, heart in 50%, brain in 32.8%, and Thrombotic Microangiopathy stigmata in 15.6%. Patients with severe retinopathy shared characteristics similar to those included in the most important cohorts already published. We also reported several additional subgroups of interest: one-third of our patients were less than 40 years old, one-third were of non-European origin, 14.3% were included through the multiorgan damage definition, without fundus severe injuries, 22.8% were treated without the use of IV therapy, 40.9% had normal or low renin level, and almost all patients were not on antihypertensive therapy at the time of the enrolment. These preliminary findings already challenge long-standing dogma, raise numerous questions, and provide a solid basis to address them in ancillary studies of the cohort.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2024
• Auteurs : Nathalia da Silva Rodrigues MendesRenato Rodrigues SilvaMoïse Kombolo-NgahPierre-Philippe RivetJerôme TondussonTatianne Ferreira de OliveiraSghaier ChrikiMarie-Pierre Ellies-OuryJean-François Hocquette
• Organismes : Unité Mixte de Recherche sur les Herbivores - UMR 1213 Universidade Federal de Goiás [Goiânia] ISARA Unité Mixte de Recherche sur les Herbivores - UMR 1213 Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Unité Mixte de Recherche sur les Herbivores - UMR 1213 Ecole Nationale Supérieure des Sciences Agronomiques de Bordeaux-Aquitaine Unité Mixte de Recherche sur les Herbivores - UMR 1213
• Publié dans Veterinary and Animal Science le 29/10/2020

---

Résumé : We hypothesized that transportation might impact beef sensory quality, particularly as the distance between farms and the slaughterhouse increases. Specifically, we expected that pre-slaughter transport over longer distances would induce stress in the cattle, resulting in elevated ultimate pH and, consequently, reduced beef quality. Thus, this study aimed to specifically study the effects of transport in commercial conditions of Limousin cows from farms located in different areas of France to slaughter on ultimate pH (pHu) measured in the Longissimus thoracis muscle (LT), marbling (two major factors affecting eating quality) and the MSA Index (a global indicator of potential eating quality at the carcass level). Cattle were studied according to distance (<50 km; between 50 and 150 km; and between 150 and 250 km from the slaughterhouse) and according to transport time from the farm to the slaughterhouse (divided into short, moderate, and extended). We found that neither distance nor transport time significantly affected pHu of beef and the other studied parameters (cold carcass weight, meat color, MSA Marbling and MSA Index). Consequently, in our commercial conditions, we concluded that the effects of transport on beef carcasses and beef eating quality of Limousin cows are negligible.

---

Fichiers liés : 2024_ Da Silva Rodrigues Mendes_Vet_Anim_Sci.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2024
• Auteurs : Mathilde AmiotLaurent MortierStéphane DalleOlivier DereureSophie DalacCaroline DutriauxMarie-Thérèse LecciaEve MaubecJean Philippe ArnaultFlorence Brunet-PossentiJulie de QuatrebarbesFlorence Granel-BrocardCaroline Gaudy-MarquesteCecile PagesPierre-Emmanuel StoebnerPhilippe SaiagThierry LesimpleDelphine LegoupilAlain DupuyHenri MontaudiéBastien OrianoCéleste LebbéRaphaël Porcher
• Organismes : Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre for Research in Epidemiology and Statistics | Centre de Recherche Épidémiologie et Statistiques Methods of therapeutic evaluation of chronic diseases | Méthodes de l’évaluation thérapeutique des maladies chroniques Centre d'épidémiologie Clinique [Hôtel-Dieu]
• Publié dans EClinicalMedicine le 01/11/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2024
• Auteurs : Julien SarkisCecile ChampyNicolas DoumercFranck BruyereMorgan RouprêtNicolas BrangerLouis SurlemontConstance MichelThibaut WaeckelBastien ParierJean-Baptiste BeauvalPierre BigotHervé LangMaxime ValleeJulien GuillotreauJean-Jacques PatardClément SarrazinStéphane de VergieOlivier BelasRomain BoissierRichard MalletFrédéric PanthierFayek TahaQuentin-Côme Le ClercLionel HoquetisFrançois AudenetLouis VignotPhilippe PaparelAlexis FontenilJean-Christophe BernhardAlexandre Ingels
• Organismes : Hôpital Hôtel Dieu de France [Beirut, Lebanon] Hôpital Henri Mondor Centre d'Investigation Clinique Henri Mondor Centre Hospitalier Universitaire de Toulouse Service d'urologie [CHRU Tours] CHU Pitié-Salpêtrière [AP-HP] Institut Paoli-Calmettes CHU Rouen Centre hospitalier Saint-Joseph [Paris] CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse] Centre Hospitalier Universitaire d'Angers Nouvel Hôpital Civil de Strasbourg Service d'urologie [CHU de Poitiers] Pharmacologie des anti-infectieux et antibiorésistance [U 1070] Clinique Pasteur [Toulouse] Service d'urologie [Rennes] = Urology [Rennes] Université Grenoble Alpes - UFR Médecine Centre Hospitalier Universitaire de Nantes = Nantes University Hospital UROLOGIE POLE LE MANS SUD Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research Clinique Francheville [Périgueux]
• Publié dans European Urology Oncology le 02/11/2020

---

Résumé : Background and objective: A hilar location for a renal tumour is sometimes viewed as a limiting factor for safe partial nephrectomy. Our aim was to evaluate perioperative, oncological, and functional outcomes of robot-assisted partial nephrectomy (RAPN) for hilar tumours (RAPN-H) in comparison to RAPN for nonhilar tumours (RAPN-NH). Methods: We conducted an observational, multicentre cohort study using prospectively collected data from the French Research Network on Kidney Cancer (UroCCR). The registry includes data for 3551 patients who underwent RAPN for localised or locally advanced renal masses between 2010 and 2023 in 29 hospitals in France. We studied the impact of a hilar location on surgery, postoperative renal function, tumour characteristics, and survival. We also compared rates of trifecta achievement (warm ischaemia time [WIT] <25 min, negative surgical margins, and no perioperative complications) between the groups. Finally, we performed a subgroup analysis of RAPN without vascular clamping. Variables were compared in univariable analysis and using multivariable linear, logistic, and Cox proportional-hazards models adjusted for relevant patient and tumour covariates. Key findings and limitations: The analytical population included 3451 patients, of whom 2773 underwent RAPN-NH and 678 underwent RAPN-H. Longer WIT (β = 2.4 min; p < 0.01), longer operative time (β = 11.4 min; p < 0.01) and a higher risk of postoperative complications (odds ratio 1.33; p = 0.05) were observed in the hilar group. Blood loss, the perioperative transfusion rate, postoperative changes in the estimated glomerular filtration rate, and trifecta achievement rates were comparable between the groups (p > 0.05). At mean follow-up of 31.9 mo, there was no significant difference in recurrence-free survival (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.58-1.2; p = 0.3), cancer-specific survival (HR 1.1, 95% CI 0.48-2.6; p = 0.79), or overall survival (HR 0.89, 95% CI 0.52-1.53; p = 0.69). Conclusions and clinical implications: Patient and tumour characteristics rather than just hilar location should be the main determinants of the optimal surgical strategy for hilar tumours. Patient summary: We found that kidney tumours located close to major kidney blood vessels led to a longer operation and a higher risk of complications during robot-assisted surgery to remove the tumour. However, tumours in these locations were not related to a higher risk of kidney function loss, cancer recurrence, or death.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2024
• Auteurs : Maxime de GuillebonRodrigue GarciaStéphane DebeugnyHugues BaderVincent ProbstNicolas BidegainKumar NarayananJacques MansouratiAymeric MenetPierre OllitraultChristelle MarquiéBenoît Guy-MoyatPierre MondolyPhilippe ChevalierNicolas BadencoNathalie BeharLaurence Jesel-MorelBertrand PierreNicolas LelloucheJean-Claude DeharoPeggy JaconFrédéric AnselmeSerge BovedaEloi Marijon
• Organismes : Centre hospitalier de Pau Service de cardiologie [CHU de Poitiers] CIC de Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402) Centre hospitalier de Pau Centre hospitalier de Pau Centre Hospitalier Universitaire de Nantes = Nantes University Hospital ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Hôpital Européen Georges Pompidou [APHP] Centre Hospitalier Régional Universitaire de Brest Optimisation des régulations physiologiques Université catholique de Lille Hôpital Saint Philibert [Lomme] Université de Caen Normandie - UFR Santé Centre Hospitalier Régional Universitaire [CHU Lille] Université de Lille Université de Limoges CHU Limoges Service Cardiologie [CHU Toulouse] Hôpital Louis Pradel [CHU - HCL] Université Claude Bernard Lyon 1 CHU Pitié-Salpêtrière [AP-HP] Laboratoire Traitement du Signal et de l'Image Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Nanomédecine Régénérative Centre de Recherche en Biomédecine de Strasbourg Nouvel Hôpital Civil de Strasbourg Centre Hospitalier Régional Universitaire de Tours CHU Henri Mondor [Créteil] Hôpital de la Timone [CHU - APHM] Aix Marseille Université Centre Hospitalier Alpes-Isère [Grenoble] CHU Rouen Clinique Pasteur [Toulouse] Hôpital Européen Georges Pompidou [APHP]
• Publié dans Heart Rhythm le 26/10/2020

---

Résumé : Background: Electrocardiographic screening before subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation is unsuccessful in around 10% of cases. A personalized screening method, by slightly moving the electrodes, to obtain a better R/T ratio has been described to overcome traditional screening failure. Objective: The objectives of the SIS study were to assess to what extent a personalized screening method improves eligibility for S-ICD implantation and to evaluate the inappropriate shock rate after such screening success. Methods: All consecutive patients eligible for an S-ICD implantation were prospectively recruited across 20 French centers between December 2019 and January 2022. In case of traditional screening failure, patients received a second personalized screening. If at least 1 vector was positive, the personalized screening was considered successful, and the patient was eligible for implantation. Results: The study included 474 patients (mean age, 50.4 ± 14.1 years; 77.4% men). Traditional screening was successful in 456 (96.2%) cases. This figure rose to 98.3% (n = 466; P = .002) when personalized screening was performed. All patients implanted after successful personalized screening had correct signal detection on initial device interrogation. Nevertheless, after 1-year follow-up, 3 of the 7 patients (43%) implanted with personalized screening experienced inappropriate shock vs 18 of the 427 patients (4.2%) with traditional screening and S-ICD implantation (P = .003). Conclusion: Traditional S-ICD screening was successful in our study in a high proportion of patients. Considering the small improvement in success of screening and a higher rate of inappropriate shock, a strategy of personalized screening cannot be routinely recommended. Clinicaltrials: gov identifier: NCT04101253

---

Fichiers liés : de Guillebon et al. - 2024 - Personalized Screening Before Subcutaneous Cardiov.pdf

---

Source